Bioprocess decisional tools to enable cell and gene therapy commercialization

Cell & Gene Therapy Insights 2019; 5(12), 1637-1643.


Published: 11 December 2019
Suzanne Farid

Suzanne Farid is Professor of Bioprocess Systems Engineering at the Advanced Centre for Biochemical Engineering at University College London (UCL) and Deputy Head of Department (Education). She is Co-Director of the Future Targeted Healthcare Manufacturing Hub in collaboration with industrial and academic consortia to revolutionize the delivery of cost-effective stratified protein-based and personalized cell-based therapies to patients. She is also Director of the UCL-AstraZeneca Centre of Excellence. She leads research on ‘Decisional Tools’ to facilitate cost-effective bioprocess design, capacity planning, R&D portfolio management, root cause analysis and manufacturability assessments for biopharmaceuticals ranging from mAbs to cell and gene therapies. She sits on the ISCT Business Models and Investment Sub Committee, UK BioIndustry Association Manufacturing Advisory Committee and is a Fellow of the IChemE. She obtained her Bachelor’s and PhD degrees in Biochemical Engineering from UCL.